Premium
Semaglutide: a new GLP‐1 analogue for type 2 diabetes
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1784
Subject(s) - medicine , semaglutide , type 2 diabetes , diabetes mellitus , endocrinology , liraglutide
Semaglutide (Ozempic) is a new once‐weekly glucagon‐like peptide‐1 (GLP‐1) analogue for the treatment of type 2 diabetes. This article examines its efficacy, adverse effects and place in therapy.